New Nano-Drug enters human testing for tough cancers
NCT ID NCT04640480
Summary
This was a first-in-human study to find a safe dose of a new experimental cancer drug called SNB-101. The drug, a nanoparticle form of an existing chemotherapy, was given by IV to 21 patients with advanced solid tumors that had stopped responding to standard treatments. The main goal was to see how much of the drug patients could tolerate and how their bodies processed it.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHA Medical Center
Seongnam-si, Gyeonggi-do, 13496, South Korea
-
The Catholic University of Korea Seoul ST. Mary's Hospital
Seoul, Seoul, 06591, South Korea
-
The Severance Hospital of the Yonsei University
Seoul, Seoul, 03722, South Korea
Conditions
Explore the condition pages connected to this study.